Aortocoronary saphenous vein graft disease: Pathogenesis, predisposition, and prevention

Circulation

Volumn 97, Issue 9, 1998, Pages 916-931

  Motwani, Joseph G ^a,b   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Atherosclerosis; Bypass; Grafting; Prevention; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; DIPYRIDAMOLE; FIBRINOGEN; HEMOSTATIC AGENT; HOMOCYSTEINE; INDOBUFEN; LIPOPROTEIN A; NITRIC OXIDE DONOR; THROMBOPLASTIN; TICLOPIDINE; VASCULOTROPIN; WARFARIN;

ARTERY GRAFT; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; CIGARETTE SMOKING; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY OBSTRUCTION; DIABETES MELLITUS; GENDER; GENE TRANSFER; GRAFT PATENCY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERNAL MAMMARY ARTERY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SAPHENOUS VEIN GRAFT; SMOKING CESSATION; STENT; SURGICAL TECHNIQUE; VEIN DISEASE; VEIN THROMBOSIS;

EID: 0032502337     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.9.916     Document Type: Review

References (133)

1. Garrett HE, Dennis EW, DeBakey ME. Aortocoronary bypass with saphenous vein graft: seven-year follow-up. JAMA. 1973;223:792-794.
2. Favaloro RG. Saphenous vein graft in the surgical treatment of coronary artery disease: operative technique. J Thorac Cardiovasc Surg. 1969;58:178-185.
3. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, Davis K, Killip T, Passman E, Norris R, Morris C, Mathur V, Varnauskas E, Chalmers TC. Effect of coronary artery bypass graft surgery on survival: overview of 10 year results from randomized trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet. 1994;344:563-570.
4. Davis KB, Chairman B, Ryan T, Bittner V, Kennedy JW. Comparison of 15 year survival for men and women after initial medical or surgical treatment for coronary artery disease: a CASS registry study. J Am Coll Cardiol. 1995;25:1000-1009.
5. Campeau L, Enjalbert M, Lesperance J, Bourassa MG, Kwiterovich P Jr, Wacholder S, Sniderman A. The relation of risk factors to the development of atherosclerosis in saphenous vein bypass grafts and the progression of disease in the native circulation: a study 10 years after aortocoronary bypass surgery. N Engl J Med. 1984;311:1329-1332.
6. Bourassa MG. Fate of venous grafts: the past, the present and the future. J Am Coll Cardiol. 1991;5:1081-1083.
7. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper D, Burton JR. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol. 1996;28:616-626.
8. Alderman EL, Corley SD, Fisher LD, Chaitman BR, Faxon DP, Foster ED, Killip T, Sosa JA, Bourassa MG. Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). J Am Coll Cardiol. 1993;22:1141-1154.
9. Cameron AA, Davis KB, Rogers WJ. Recurrence of angina after coronary artery bypass surgery: predictors and prognosis (CASS Registry). J Am Coll Cardiol. 1995;4:895-899.
10. Weintraub WS, Jones EL, Craver JM, Guyton RA. Frequency of repeat coronary bypass or coronary angioplasty after coronary artery bypass surgery using saphenous venous grafts. Am J Cardiol. 1994;73:103-112.
11. Loop FD, Lytle BW, Cosgrove DM, Woods EL, Stewart RW, Golding AR, Goormastic M, Taylor PC. Reoperation for coronary atherosclerosis: changing practice in 2509 consecutive patients. Ann Surg. 1990;212:378-386.
12. Cameron A, Kemp HG Jr, Green GE. Reoperation for coronary artery disease: 10 years of clinical follow-up. Circulation. 1988;78(suppl I):I-158-I-162.
13. Hannan EL, Kilburn H, O'Donnell JF, Lukacik G, Shields EP. Adult open heart surgery in New York State. JAMA. 1990;264:2768-2774.
14. Lefkovits J, Holmes DR, Califf RM, Safian RD, Pieper K, Keeler G, Topol EJ. Predictors and sequelae of distal embolization during saphenous vein graft intervention from the CAVEAT-II trial: Coronary Angioplasty Versus Excisional Atherectomy Trial. Circulation. 1995;92:734-740.
15. de Jaegere PP, van Domburg RT, DeFeyter PJ, Ruygrok PN, van der Giessen WJ, van den Brand MJ, Serruys PW. Long-term clinical outcome after stent implantation in saphenous vein grafts. J Am Coll Cardiol. 1996;28:89-96.
16. Fischman DL, Savage MP, Bailey S, Werner JA, Rake R, Goldberg S. Predictors of restenosis after saphenous vein graft interventions. Circulation. 1996;94(suppl I):I-621. Abstract.
17. Ellis SG, Brener SJ, DeLuca S, Tuzcu EM, Raymond RE, Whitlow PL, Topol EJ. Late myocardial ischemic events after saphenous vein graft intervention - importance of initially 'nonsignificant' vein graft lesions. Am J Cardiol. 1997;79:1460-1464.
18. Cox JL, Chiasson DA, Gotlieb AI. Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. Prog Cardiovasc Dis. 1991;34:45-68.
19. Roubos N, Rosenfeldt FL, Richards SM, Conyers RAJ, Davis BB. Improved preservation of saphenous vein grafts by the use of glyceryl trinitrate - verapamil solution during harvesting. Circulation. 1995;92(suppl II):II-31-II-36.
20. Verrier ED, Boyle EM Jr. Endothelial cell injury in cardiovascular surgery. Ann Thorac Surg. 1996;62:915-922.
21. Dilley RJ, McGeachie JK, Tennant M. Vein to artery grafts: a morphological and histochemical study of the histogenesis of intimal hyperplasia. Aust N Z J Surg. 1992;62:297-303.
22. Nachman RL, Silverstein R. Hypercoagulable states. Ann Intern Med. 1993;119:819-827.
23. Cook JM, Cook CD, Marlar R, Solis MM, Fink L, Eidt JF. Thrombomodulin activity in human saphenous vein grafts prepared for coronary artery bypass. J Vasc Surg. 1991;14:147-151.
24. Angelini GD, Christie MI, Bryan AJ, Lewis MJ. Surgical preparation impairs release of endothelium-derived relaxing factor from human saphenous vein. Ann Thorac Surg. 1989;48:417-420.
25. Allaire E, Clowes AW. Endothelial cell injury in cardiovascular surgery: the intimal hyperplastic response. Ann Thorac Surg. 1997;63:582-591.
26. Moor E, Hamsten A, Blomback M, Herzfeld I, Wiman B, Ryden L. Haemostatic factors and inhibitors and coronary artery bypass grafting: preoperative alterations and relations to graft occlusion. Thromb Haemost. 1994;72:335-342.
27. Mannucci L, Gerometta PS, Mussoni L, Antona C, Parolari A, Salvi L, Biglioli P, Tremoli E. One month follow-up of haemostatic variables in patients undergoing aortocoronary bypass surgery: effect of aprotinin. Thromb Haemost. 1995;73:356-361.
28. te Velthuis H, Jansen PGM, Oudemans-van Straaten HM, Van Kamp GJ, Sturk A, Eijsman L, Wildevuur CRH. Circulating endothelin in cardiac operations: influence of blood pressure and endotoxin. Ann Thorac Surg. 1996;61:904-908.
29. Yang Z, Ruschitzka F, Rabelink TJ, Noll G, Julmy F, Joch H, Gafner V, Aleksic I, Althaus U, Luscher TF. Different effects of thrombin receptor activation on endothelium and smooth muscle cells of human coronary bypass vessels: implications for venous bypass graft failure. Circulation. 1997;95:1870-1876.
30. Thiene G, Miazzi P, Valsecchi M, Valente M, Bortolotti U, Casarotto D, Gallucci V. Histological survey of the saphenous vein before its use as autologous aortocoronary bypass graft. Thorax. 1980;35:519-522.
31. Chesebro JM, Fuster V. Platelet-inhibitor drugs before and after coronary artery bypass surgery and coronary angioplasty: the basis of their use, data from animal studies, clinical trial data, and current recommendations. Cardiology. 1986;73:292-305.
32. Stary HC, Blankenhorn DH, Bleakley Chandler A, Glagov S, Insull W Jr. Richardson M, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, Wissler RW. A definition of the intima of human arteries and its atherosclerosis-prone regions: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1992;85:391-405.
33. Holt CM, Francis SE, Newby AC, Rogers S, Gadsdon PA, Taylor T, Angelini GD. Comparison of response to injury in organ culture of human saphenous vein and internal mammary artery. Ann Thorac Surg. 1993;55:1522-1528.
34. Rao GN, Berk BC. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res. 1992;70:593-599.
35. Shi Y, O'Brien, JE Jr, Mannion JD, Morrison RC, Chung W, Fard A, Zalewski A. Remodeling of autologous saphenous vein grafts: the role of perivascular myofibroblasts. Circulation. 1997;95:2684-2693.
36. Nguyen HC, Grossi EA, LeBoutillier M III, Steinberg BM, Rifkin DB, Baumann FG, Colvin SB, Galloway AC. Mammary artery versus saphenous vein grafts: assessment of basic fibroblast growth factor receptors. Ann Thorac Surg. 1994;58:308-311.
37. Chen L, Theroux P, Lesperance J, Shabani F, Thibault B, DeGuise P. Angiographic features of vein grafts versus ungrafted coronary arteries in patients with unstable angina and previous bypass surgery. J Am Coll Cordiol. 1996;28:1493-1499.
38. Douglas JS Jr. Percutaneous approaches to recurrent myocardial ischemia in patients with prior surgical revascularization. Semin Thorac Cardiovasc Surg. 1994;6:98-108.
39. Lie JT, Lawrie GM, Morris GC. Aortocoronary bypass saphenous vein graft atherosclerosis: anatomic study of 99 vein grafts from normal and hyperlipoproteinemic patients up to 75 months postoperatively. Am J Cardiol. 1977;40:906-914.
40. Kalan JM, Roberts WC. Morphologic findings in saphenous veins used as coronary arterial bypass conduits for longer than 1 year: necropsy analysis of 53 patients, 123 saphenous veins, and 1865 five-millimeter segments of veins. Am Heart J. 1990;119:1164-1184.
41. Neitzel GF, Barboriak JJ, Pintar K, Qureshi I. Atherosclerosis in aortocoronary bypass grafts: morphologic study and risk factor analysis 6 to 12 years after surgery. Arteriosclerosis. 1986;6:594-600.
42. Ratliff NB, Myles JL. Rapidly progressive atherosclerosis in aortocoronary saphenous vein grafts: possible immune-mediated disease. Arch Pathol Lab Med. 1989;113:772-776.
43. Stary HC, Bleakley Chandler A, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a Report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association, Circulation. 1995;92:1355-1374.
44. Boyle EM Jr, Lille ST, Allaire E, Clowes AW, Verrier ED. Endothelial cell injury in cardiovascular surgery: atherosclerosis. Ann Thorac Surg. 1997;63:885-894.
45. Nishioka T, Luo H, Berglund H, Eigler NL, Kim CJ, Tabak SW, Siegel RJ. Absence of focal compensatory enlargement or constriction in diseased human coronary saphenous vein bypass grafts: an intravascular ultrasound study. Circulation. 1996;93:683-690.
46. Shafi S, Palinski W, Born GVR. Comparison of uptake and degradation of low density lipoproteins by arteries and veins of rabbits. Atherosclerosis. 1987;66:131-138.
47. Larson RM, Hagen PO, Fuchs JCA. Lipid biosynthesis in arteries, veins and venous grafts. Circulation. 1974;50(suppl III):III-139. Abstract.
48. Walts AE, Fishbein MC, Matloff JM. Thrombosed, ruptured atheromatous plaques in saphenous vein coronary artery bypass grafts: ten years' experience. Am Heart J. 1987;114:718-723.
49. Solymoss BC, Nadeau P, Millette D, Campeau L. Late thrombosis of saphenous vein coronary bypass grafts related to risk factors. Circulation. 1988;78(suppl I):I-140-I-143.
50. Kockx MM, DeMeyer GRY, Bortier H, deMeyere N, Muhring J, Bakker A, Jacob W, vanVaeck L, Herman A. Luminal foam cell accumulation is associated with smooth muscle cell death in the intimal thickening of human saphenous vein grafts. Circulation. 1996;94:1255-1262.
51. Roth JA, Cukingnan RA, Brown BG, Gocka E, Carey JS. Factors influencing patency of saphenous vein grafts. Ann Thorac Surg. 1979;28: 176-183.
52. Cataldo G, Braga M, Pirotta N, Lavezzari M, Rovelli F, Marubini E, on behalf of Studio Indobufene nel Bypass Aortocoronarico (SINBA). Factors influencing 1-year patency of coronary artery saphenous vein grafts: Studio Indobufene nel Bypass Aortocoronarico (SINBA). Circulation. 1993;88(suppl II):II-93-II-98.
53. Cosgrove DM, Loop FD, Saunders CL, Lytle BW, Kramer JR. Should coronary arteries with less than fifty percent stenosis be bypassed? J Thorac Cardiovasc Surg. 1981;82:520-530.
54. Campos EE, Cinderella JA, Farhi ER. Long-term angiographic follow-up of normal and minimally diseased saphenous vein grafts. J Am Coll Cardiol. 1993;21:1175-1180.
55. Mehta ID, Zaret BL, Weinberg J, Kopf GS, Elefteriades JA. Should disease-free saphenous vein grafts be replaced at the time of redo CABG. Circulation. 1996;94(suppl I):I-412-I-413. Abstract.
56. Noyez L, van der Werf T, Klinkenberg TJ, Janssen DPB, Kaan GL, Lacquet LK. Experience and early results of second reoperations for coronary artery disease: should patent vein grafts be replaced during reoperation? J Thorac Cardiovasc Surg. 1994;107:684-689.
57. Fitzgibbon GM, Leach AJ, Kafka HP. Atherosclerosis of coronary artery bypass grafts and smoking. Can Med Assoc J. 1987;136:45-47.
58. Bosch X, Perez-Villa F, Sanz G. Effect of smoking habits on the preventive effect of aspirin and dipyridamole on early aortocoronary bypass occlusion. Eur Heart J. 1991;12:170. Abstract.
59. European Coronary Surgery Study Group. Long-term results of prospective randomised study of coronary artery bypass surgery in stable angina pectoris. Lancet. 1982;2:1173-1180.
60. Cavender JB, Rogers WJ, Fisher LD, Gersh BJ, Coggin CJ, Myers WO. Effects of smoking on survival and morbidity in patients randomized to medical or surgical therapy in the Coronary Artery Surgery Study (CASS): 10 year follow-up. J Am Coll Cardiol 1992;20:287-294.
61. Voors AA, van Brussel BL, Plokker T, Ernst SMPG, Ernst NM, Koomen EM, Tyssen JGP, Vermeulen FEE. Smoking and cardiac events after venous coronary bypass surgery: a 15-year follow-up study. Circulation. 1996;93:42-44.
62. Daida H, Yokoi H, Miyano H, Mokuno H, Satoh H, Kottke TE, Hosoda Y, Yamaguchi H. Relation of saphenous vein graft obstruction to serum cholesterol levels. J Am Coll Cardiol. 1995;25:193-197.
63. Fox MH, Gruchow HW, Barboriak JJ, Anderson AJ, Hoffman RG, Flemma RU, King JF. Risk factors among patients undergoing repeat aorta-coronary bypass procedures. J Thorac Cardiovasc Surg. 1987;93:56-61.
64. van Brussel BL, Plokker T, Ernst SMPG, Ernst NM, Knaepen PJJ, Koomen EM, Tyssen JGP, Vermeulen FEE, Voors AA. Venous coronary artery bypass surgery: a 15-year follow-up study. Circulation. 1993;88:87-92.
65. Kugiyama K, Sakamoto T, Misumi I, Sugiyama S, Ohgushi M, Ogawa H, Horiguchi M, Yasue H. Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells. Circ Res. 1993;73:335-343.
66. Linden T, Bondjers G, Karlsson T, Wiklund O. Serum triglycerides and HDL cholesterol: major predictors of long-term survival after coronary surgery. Eur Heart J. 1994;15:747-752.
67. Frye RL, Kronmal R, Schaff HV, Myers WO, Gersh BJ. Stroke in coronary artery bypass graft surgery: an analysis of the CASS experience: the participants in the Coronary Artery Surgery Study. Int J Cardiol. 1992;36:213-221.
68. Atkinson JB, Forman MB, Vaughn WK, Robinowitz M, McAllister HA, Virmani R. Morphologic changes in long-term saphenous vein bypass grafts. Chest. 1985;88:341-348.
69. Iwinski J, Iwinska A, Ochala A. Haemodynamic properties of the internal mammary artery and saphenous vein in young persons and patients with moderate hypertension. Eur Heart J. 1996;8:546. Abstract.
70. Morris JJ, Smith LR, Jones RH, Glower DD, Morris PB, Muhlbaier LH, Reves JG, Rankin JS. Influence of diabetes and mammary artery grafting on survival after coronary bypass. Circulation. 1991;84(suppl III):III-275-III-284.
71. Lawrie GM, Morris GC Jr, Glaeser DH. Influence of diabetes mellitus on the results of coronary bypass surgery: follow-up of 212 diabetic patients ten to 15 years after surgery. JAMA. 1986;256:2967-2971.
72. Brunkwall JS, Bergqvist D. Prostacyclin release from the human saphenous vein in diabetics is lower than in non-diabetics. World J Surg. 1992;16:1141-1146.
73. Loop FD, Golding LR, MacMillan JP, Cosgrove DM, Lytle BW, Sheldon WC. Coronary artery surgery in women compared with men; analyses of risks and long-term results. J Am Coll Cardiol. 1983;1:383-390.
74. Brandrup-Wognsen G, Berggren H, Hartford M, Hjalmarson A, Karlson T, Herlitz J. Female sex is associated with increased mortality and mor- bidity early, but not late, after coronary artery bypass grafting. Eur Heart J. 1996;17:1426-1431.
75. O'Connor NJ, Morton JR, Birkmeyer JD, Olmstead EM, O'Connor GT, for the Northern New England Cardiovascular Disease Study Group. Effect of coronary artery diameter in patients undergoing coronary bypass surgery. Circulation. 1996;93:652-655.
76. Sullivan JM, El-Zeky F, Vander Zwaag R, Ramanathan KB. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. Am J Cardiol, 1997;79:847-850.
77. Cobbaert C, Sergeant P, Meyns B, Szecsi J, Kesteleot H. Time course of serum Lp(a) in men after coronary artery bypass grafting. Acta Cardiol. 1992;47:529-542.
78. Cushing CL, Gaubatz JW, Nava ML, Burdick BJ, Bocan TMA, Guyton JR, Weilbaecher D, DeBakey ME, Lawrie CM, Morrisett JD. Quantitation and localization of apolipoproteins (a) and B in coronary artery bypass vein grafts resected at reoperation. Arteriosclerosis. 1989;9:593-603.
79. Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U. Detection and quantification of lipoprotein (a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 1989;9:579-592.
80. Hoff HF, Beck GJ, Skibinski CI, Jurgens G, O'Neil J, Kramer J, Lytle B. Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients. Circulation, 1988;77:1238-1244.
81. Eritsland J, Arnesen H, Seljeflot I, Abdelnoor M, Gronseth K, Berg K, Malinow MR. Influence of serum lipoprotein (a) and homocysteine levels on graft patency after coronary artery bypass grafting. Am J Cardiol. 1994;74:1099-1102.
82. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 1996;27:517-527.
83. Meade TW. Fibrinogen in ischaemic heart disease. Eur Heart J. 1995; 16(suppl A):31-35.
84. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
85. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up. JAMA. 1990;264:3013-3017.
86. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 1997;336:153-162.
87. Sacks FM, Pfeffer MA, Move LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMC, Wun CC, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J. Med. 1996;335:1001-1009.
88. White CW, Campeau L, Domanski M, Forrester J, Geller N, Gobel F, Herd JA, Hoogwerf B, Hunninghake D, Knatterud G, Rosenberg Y, Rosza Z, for the Post-CABG Investigators. Influence of saphenous vein graft (SVG) age on effectiveness of an aggressive lipid lowering strategy to prevent SVG atherosclerosis: results from the NHLBI PostCABG trial. J Am Coll Cardiol. 1997;29:400A. Abstract.
89. Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, Doherty J, Read R, Chesler E, Sako Y, Lancaster L, Emery R, Sharma GVRK, Josa M, Pacold I, Montoya A, Parikh D, Sethi G, Holt J, Kirklin J, Shabetai R, Moores W, Aldridge J, Masud Z, Demots H, Floten S, Haakenson C, Harker LA. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation. 1988;6:1324-1332.
90. Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, Doherty J, Read R, Chesler E, Sako Y, Lancaster L, Emery R, Sharma GVRK, Josa M, Pacold I, Montoya A, Parikh D, Sethi G, Holt J, Kirklin J, Shabetai R, Moores W, Aldridge J, Masud Z, DeMots H, Floten S, Haakenson C, Harker LA. Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation. 1989;80:1190-1197.
91. Stein PD, Dalen JE, Goldman S, Schwartz L, Theroux P, Turpie AGG. Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts. Chest. 1995;108:424S-430S.
92. van der Meer J, Hillege HL, Kootstra GJ, Ascoop CAPL, Pfisterer M, van Gilst WH, Lie KI, for the CABADAS research group. Prevention of one-year vein graft occlusion after aortocoronary bypass surgery: a com parison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral anticoagulants. Lancet. 1993;342:257-264.
93. Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Outt T, Kern KB, Sethi G, Sharma GVRK, Khuri S, Richards K, Grover F, Morrison D, Whitman G, Chesler E, Sako Y, Pacold I, Montoya A, DeMots H, Floten S, Doherty J, Read R, Scott S, Spooner T, Masud Z, Haakemon C, Kim T, Harker LA. Long-term graft patency (3 years) after coronary artery surgery: effects of aspirin: results of a VA cooperative study. Circulation. 1994;89:1138-1143.
94. Landymore RW, MacAuley MA, Fris J. Effect of aspirin on intimal proliferation and tissue cholesterol in long-term experimental bypass grafts. Eur J Cardiothorac Surg. 1992;6:422-426.
95. Ratnatunga CP, Edmondson SF, Rees GM, Kovacs IB. High-dose aspirin inhibits shear-induced platelet reaction involving thrombin generation. Circulation. 1992;85:1077-1082.
96. Buchanan MR, Brister SJ. Individual variation in the effects of aspirin on platelet function: implications for the use of ASA clinically. Can J Cardiol. 1995;11:221-227.
97. The Studio Indobufene nel Bypass Aortocoronarico (SINBA) Group. Indobufen versus aspirin plus dipyridamole after coronary artery bypass surgery. Conn Artery Dis. 1991;2:897-906.
98. Rajah SM, Nair U, Rees M, Saunders N, Walker G, Williams G, Critchley A, Beton D, Campbell C, Lawson RA, Rahman A, Nair KK, Dyet J, Kushwaha S, Rees A, Powell JD, Drake J. Effects of antiplatelet therapy with indobufen or aspirin-dipyridamole on graft patency one year after coronary artery bypass grafting. J Thorac Cardiovasc Surg. 1994;107:1146-1153.
99. Chevigne M, David JL, Rigo P, Limet R. Effect of ticlopidine on saphenous vein bypass patency rates: a double-blind study. Ann Thorac Surg. 1984;37:371-378.
100. Limet R, David JL, Magotteaux P, Larock MP, Rigo P. Prevention of aorta-coronary bypass graft occlusion: beneficial effect of ticlopidine on early and late patency rates of venous coronary bypass grafts: a double-blind study. J Thorac Cardiovasc Surg. 1987;94:773-783.
101. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K. A randomized comparison of amiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996;334:1084-1089.
102. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
103. Gohlke H, Gohlke-Barwolf C, Sturzenhofecker P, Gornandt L, Ritter B, Reichelt M, Buchwalsky R, Schmuziger M, Roskamm H. Improved graft patency with anticoagulant therapy after aortocoronary bypass surgery: a prospective, randomized study. Circulation. 1981;64(suppl II): II-22-II-27.
104. Kolessov VI. Mammary artery-coronary artery anastomosis as method of treatment for angina pectoris. J Thorac Cardiovasc Surg. 1967;54:535-544.
105. Loop FD. Internal-thoracic-artery grafts: biologically better coronary arteries. N Engl J Med. 1996;334:263-265.
106. Cameron A, Davis KB, Green G, Schaff HV. Coronary bypass surgery with internal thoracic artery grafts: effects on survival over a 15-year period. N Engl J Med. 1996;334:216-219
107. Dewar LRS, Jamieson WRE, Janusz MT, Adeli-Sardo M, Germann E, MacNab JS, Tyers FO. Unilateral versus bilateral internal mammary revascularization: survival and event-free performance. Circulation. 1995;92(suppl II):II-8-II-13.
108. Nottin R, Grinda JM, Anidjar S, Folliquet T, Detroux M. Coronary-coronary bypass graft: an arterial conduit-sparing procedure. J Thorac Cardiovasc Surg. 1996;112:1223-1230.
109. Rabah MM, Gangadharan V, Brodsky M, Safian RD. Unstable coronary ischemic syndromes caused by coronary-subclavian steal. Am Heart J. 1996;131:374-378.
110. Sbarouni E, Corr L, Fenech A. Microcoil embolization of large intercostal branches of internal mammary artery grafts. Cathet Cardiovasc Diagn. 1994;31:334-336.
111. Barner HB. New arterial conduits for coronary bypass surgery. Semin Thorac Cardiovasc Surg. 1994;6:78-80.
112. Dietl CA, Benoit CH, Gilbert CL, Woods EL, Pharr WF, Berkheimer MD, Madigan NP, Menapace FJ. Which is the graft of choice for the right coronary and posterior descending arteries? Comparison of the right internal mammary and the right gastroepiploic artery. Circulation. 1995;92(suppl II):II-92-II-97.
113. Pym J, Brown P, Pearson M, Parker J. Right gastroepiploic-to-coronary artery bypass. The first decade of use. Circulation. 1995;92(suppl II):II-45-II-49.
114. Grandjean GJ, Boonstra PW, denHeyer P, Ebels T. Arterial revascularization with the right gastroepiploic artery and internal mammary arteries in 300 patients. J Thorac Cardiovasc Surg. 1994;107:1309-1315.
115. Brodman RF, Frame R, Camacho M, Hu E, Chen A, Hollinger I. Routine use of unilateral and bilateral radial arteries for coronary artery bypass graft surgery. J Am Coll Cardiol. 1996;28:959-963.
116. Manasse E, Sperti G, Suma H, Canosa C, Kol A, Martinelli L, Schiavello R, Crea F, Maseri A, Possati GF. Use of the radial artery for myocardial revascularization. Ann Thorac Surg. 1996;62:1076-1083.
117. Buche M, Schroeder E, Gurne O, Chenu P, Paquay JL, Marchandise B, Eucher P, Louagie Y, Dion R. Schoevaerdts JC. Coronary artery bypass grafting with the inferior epigastric artery. Midterm clinical and angiographic results. J Thorac Cardiovasc Surg. 1995;109:553-560.
118. Calafiore AM, Angelini GD, Bergsland J, Salerno TA. Minimally invasive coronary artery bypass grafting. Ann Thorac Surg. 1996;62:1545-1548.
119. Calafiore AM, Di Giammarco G, Teodori G, Bosco G, D'Annunzio E, Barsotti A, Maddestra N, Paloscia L, Vitolla G, Sciarra A, Fino C, Contini M. Left anterior descending coronary artery grafting via left anterior small thoracotomy without cardiopulmonary bypass. Ann Thorac Surg. 1996;61: 1658-1665.
120. Boonstra PW, Grandjean JG, Mariani MA. Reoperative coronary bypass grafting without cardiopulmonary bypass through a small thoracotomy. Ann Thorac Surg. 1997;63:405-407.
121. Angelini GD, Wilde P, Salerno TA, Bosco G, Calafiore AM. Integrated left small thoracotomy and angioplasty for multivessel coronary artery revascularisation. Lancet. 1996;347:757-758.
122. Friedrich GJ, Bonatti J, Dapunt OE. Preliminary experience with minimally invasive coronary-artery bypass surgery combined with coronary angioplasty. N Engl J Med. 1997;336:1454. Letter.
123. Chen SJ, Wilson JM, Muller DWM. Adenovirus-mediated gene transfer of soluble vascular cell adhesion molecule to porcine interposition vein grafts. Circulation. 1994;89:1922-1928.
124. Cable DG, O'Brien T, Schaff HV, Katusic ZS, Pompili VJ. Adenoviral transfection of human saphenous veins with eNOS: gene therapy applied to coronary bypass conduits. Circulation. 1996;94(suppl I):I-295. Abstract.
125. Imagawa H, Taniguchi K, Takahashi T. Gene transfer with hemagglutinating virus of Japan-liposome into human saphenous vein graft: preventive way against vein graft disease. Circulation, 1996;94(suppl I):I-477. Abstract.
126. Mann MJ, Gibbons GH, Kernoff RS, Diet FP, Tsao PS, Cooke JP, Kaneda Y, Dzau VJ. Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci U S A. 1995;92:4502-4506.
127. Dunn PF, Newman KD, Jones M, Yamada I, Shayani V, Virmani R, Dichek DA. Seeding of vascular grafts with genetically modified endothelial cells: secretion of recombinant tPA results in decreased seeded cell retention in vitro and in vivo. Circulation. 1996;93:1439-1446.
128. deBelder A, Salas E, Langford E, Marrinan M, Martin JF. S-nitrosoglutathione inhibits coronary artery vein graft platelet activation in vivo. Eur Heart J. 1996;17(suppl):545. Abstract.
129. Hanna AK, Fox JC, Swain JL, Neschis DG, Safford SD, Golden MA. Antiense basic FGF (bFGF) gene transfer reduces intimal thickening. Circulation. 1996;94(suppl I):I-705. Abstract.
130. Asahara T, Bauters C, Pastore C, Kearney M, Rossow S, Bunting S, Ferrara N, Symes JF, Isner JM. Local delivery of vascular endothelial growth factor accelerates re-endothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation. 1995;91:2793-2801.
131. Channon KM, Fulton GJ, Davies MG, Peters KG, Ezekeowitz MD, Hagen PO, Annex BH. CD18-positive leukocytes mediate tissue factor expression in early experimental vein grafts. Circulation, 1996;94(suppl I):I-695. Abstract.
132. Annex BH, Fulton GJ, Channon KM, Davies MG, Peters KG, Ezekowitz MD, Hagen PO. Local delivery of an anti-tissue factor antibody decreases leukocyte infiltration but fails to limit intimal hyperplasia in experimental vein grafts. Circulation. 1996;94(suppl I):I-4. Abstract.
133. Izzat MB, Mehta D, Bryan AJ, Reeves B, Newby AC, Angelini GD. Influence of external stent size on early medial and neointimal thickening in a pig model of saphenous vein bypass grafting. Circulation. 1996;94:1741-1745.